Copy to clipboard 
Aclarion executed a strategic partnership agreement solidifying the previously signed non-binding Letter of Intent with ATEC.
Uniting the structural information powered by ATEC’s AlphaInformatiX platform with the biomarker data that enables Aclarion’s Nociscan solution to help identify potentially painful discs will provide surgeons with unprecedented data on one platform. That platform will be designed to improve clinical outcomes, while reducing overall procedural costs for patients with chronic low back pain.
The agreement maps out a multi-step strategic partnership in which ATEC and Aclarion have committed to work together to identify key opinion leader surgeons to evaluate the Nociscan technology. Feedback from the surgeons will inform clinical evaluations designed to assess the utility of Nociscan in conjunction with EOS imaging, the foundation of ATEC’s AlphaInformatiX platform.
ATEC and Aclarion intend to co-market Nociscan in targeted markets. In exchange for select access to ATEC’s surgeon network for the evaluation and advancement of Nociscan, Aclarion has agreed to provide ATEC with certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.
Aclarion’s proprietary decision-support tool, Nociscan, is an evidence-supported SaaS platform designed to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight whether a disc may be a source of pain. When used with other diagnostic tools, Nociscan may provide critical insights into the location of a patient’s low back pain.
Pat Miles, Chairman and CEO of ATEC, commented, “Moving from our previously signed LOI to this agreement in just a matter of weeks demonstrates our shared vision for the solution we can create together. We share an intent to move through the phases of the agreement efficiently and have already identified internal leaders and resources to accomplish the first phase in the weeks to come. We believe in the importance of biochemical markers within the treatment paradigm and by partnering with Aclarion, we can progress toward a mutual objective to integrate and advance technologies that improve the predictability and reproducibility of spine patient care.”
Source: Aclarion, Inc.
Aclarion executed a strategic partnership agreement solidifying the previously signed non-binding Letter of Intent with ATEC.
Uniting the structural information powered by ATEC’s AlphaInformatiX platform with the biomarker data that enables Aclarion’s Nociscan solution to help identify potentially painful discs will provide surgeons with...
Aclarion executed a strategic partnership agreement solidifying the previously signed non-binding Letter of Intent with ATEC.
Uniting the structural information powered by ATEC’s AlphaInformatiX platform with the biomarker data that enables Aclarion’s Nociscan solution to help identify potentially painful discs will provide surgeons with unprecedented data on one platform. That platform will be designed to improve clinical outcomes, while reducing overall procedural costs for patients with chronic low back pain.
The agreement maps out a multi-step strategic partnership in which ATEC and Aclarion have committed to work together to identify key opinion leader surgeons to evaluate the Nociscan technology. Feedback from the surgeons will inform clinical evaluations designed to assess the utility of Nociscan in conjunction with EOS imaging, the foundation of ATEC’s AlphaInformatiX platform.
ATEC and Aclarion intend to co-market Nociscan in targeted markets. In exchange for select access to ATEC’s surgeon network for the evaluation and advancement of Nociscan, Aclarion has agreed to provide ATEC with certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.
Aclarion’s proprietary decision-support tool, Nociscan, is an evidence-supported SaaS platform designed to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight whether a disc may be a source of pain. When used with other diagnostic tools, Nociscan may provide critical insights into the location of a patient’s low back pain.
Pat Miles, Chairman and CEO of ATEC, commented, “Moving from our previously signed LOI to this agreement in just a matter of weeks demonstrates our shared vision for the solution we can create together. We share an intent to move through the phases of the agreement efficiently and have already identified internal leaders and resources to accomplish the first phase in the weeks to come. We believe in the importance of biochemical markers within the treatment paradigm and by partnering with Aclarion, we can progress toward a mutual objective to integrate and advance technologies that improve the predictability and reproducibility of spine patient care.”
Source: Aclarion, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
